MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Proceeds-Convertible12Promissory Notes$1,800K Proceeds from capitalcontributions$1,745K Proceeds-Convertible Bridge Loans$90K Proceeds from conversionof warrants to...$11K Net cash provided byfinancing activities$2,646K Canceled cashflow$1,000K Net (decrease)increase in cash, cash...-$206K Canceled cashflow$2,646K Net income (loss)$15,350K Accounts payable andaccrued expenses$1,079K Loss on issuance offinancial instruments...-$1,050K Stock-based compensation$707K Noncash interestexpense (including...$403K Depreciation andamortization$341K Amortization of right-of-useasset$38K Payment of revolvingline of credit$1,000K Net cash used inoperating activities-$2,800K Canceled cashflow$18,968K Net cash (used in)provided by investing...-$52K Change in fair value offinancial instruments...$21,575K Prepaid expenses andother current assets$128K Operating lease liability-$40K Other currentliabilities-$25K Purchases of capitalizedsoftware$52K
Cash Flow
source: myfinsight.com

NKGen Biotech, Inc. (NKGN)

NKGen Biotech, Inc. (NKGN)